Literature DB >> 22576957

Ginseng reverses established cardiomyocyte hypertrophy and postmyocardial infarction-induced hypertrophy and heart failure.

Melissa Moey1, Xiaohong T Gan, Cathy Xiaoling Huang, Venkatesh Rajapurohitam, Eduardo Martínez-Abundis, Edmund M K Lui, Morris Karmazyn.   

Abstract

BACKGROUND: A major challenge in the treatment of heart failure is the ability to reverse already-established myocardial remodeling and ventricular dysfunction, with few available pharmacological agents prescribed for the management of heart failure having demonstrated successful reversal of the remodeling and hypertrophic processes. North American ginseng (Panax quinquefolius) has previously been shown to effectively prevent cardiomyocyte hypertrophy and heart failure. Here, we determined whether North American ginseng can reverse established cardiomyocyte hypertrophy in cultured myocytes as well as hypertrophy and left ventricular dysfunction in experimental heart failure secondary to coronary artery occlusion. METHODS AND
RESULTS: Ginseng was administered in drinking water (0.9 g/L) ad libitum to rats after 4 weeks of sustained coronary artery ligation when heart failure was established or to angiotensin II- (100 nmol/L), endothelin-1- (10 nmol/L), or phenylephrine- (10 µmol/L) induced hypertrophic cultured neonatal ventricular cardiomyocytes. Echocardiographic and catheter-based measurements of hemodynamic parameters 4 weeks after starting ginseng treatment (8 weeks postinfarction) revealed nearly complete reversibility of systolic and diastolic abnormalities. Similarly, ginseng administration to hypertrophic cardiomyocytes resulted in a complete reversal to a normal phenotype after 24 hours as determined by cell surface area and expression of molecular markers. The effects of ginseng both in vivo and in cultured cardiomyocytes were associated with reversal of calcineurin activation and reduced nuclear translocation of the transcription factor NFAT3 (nuclear factor of activated T cells 3) in cultured myocytes. Moreover, the beneficial effect of ginseng was associated with normalization in the gene expression of profibrotic markers, including collagen (I and III) and fibronectin.
CONCLUSIONS: This study demonstrates a marked ability of ginseng to reverse cardiac hypertrophy, myocardial remodeling, and heart failure, which was associated with and likely mediated by reversal of calcineurin activation. Ginseng may offer a potentially effective approach to reverse the myocardial remodeling and heart failure processes, particularly in combination with other treatment modalities.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22576957     DOI: 10.1161/CIRCHEARTFAILURE.112.967489

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  11 in total

1.  VEGF-C/VEGFR-3 pathway promotes myocyte hypertrophy and survival in the infarcted myocardium.

Authors:  Tieqiang Zhao; Wenyuan Zhao; Weixin Meng; Chang Liu; Yuanjian Chen; Ivan C Gerling; Karl T Weber; Syamal K Bhattacharya; Rahul Kumar; Yao Sun
Journal:  Am J Transl Res       Date:  2015-04-15       Impact factor: 4.060

2.  Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3.

Authors:  Rongrong Jiang; Jiajia Dong; Xiuxue Li; Feifei Du; Weiwei Jia; Fang Xu; Fengqing Wang; Junling Yang; Wei Niu; Chuan Li
Journal:  Br J Pharmacol       Date:  2015-01-20       Impact factor: 8.739

3.  Multiple circulating saponins from intravenous ShenMai inhibit OATP1Bs in vitro: potential joint precipitants of drug interactions.

Authors:  Olajide E Olaleye; Wei Niu; Fei-Fei Du; Feng-Qing Wang; Fang Xu; Salisa Pintusophon; Jun-Lan Lu; Jun-Ling Yang; Chuan Li
Journal:  Acta Pharmacol Sin       Date:  2018-10-16       Impact factor: 6.150

4.  A systems genetics approach identifies Trp53inp2 as a link between cardiomyocyte glucose utilization and hypertrophic response.

Authors:  Marcus M Seldin; Eric D Kim; Milagros C Romay; Shen Li; Christoph D Rau; Jessica J Wang; Karthickeyan Chella Krishnan; Yibin Wang; Arjun Deb; Aldons J Lusis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-02-24       Impact factor: 4.733

5.  Illuminating drug action by network integration of disease genes: a case study of myocardial infarction.

Authors:  Rui-Sheng Wang; Joseph Loscalzo
Journal:  Mol Biosyst       Date:  2016-04-26

6.  American ginseng acutely regulates contractile function of rat heart.

Authors:  Mao Jiang; Juan M Murias; Tom Chrones; Stephen M Sims; Edmund Lui; Earl G Noble
Journal:  Front Pharmacol       Date:  2014-03-14       Impact factor: 5.810

7.  Cardiac microvascular barrier function mediates the protection of Tongxinluo against myocardial ischemia/reperfusion injury.

Authors:  Kang Qi; Lujin Li; Xiangdong Li; Jinglin Zhao; Yang Wang; Shijie You; Fenghuan Hu; Haitao Zhang; Yutong Cheng; Sheng Kang; Hehe Cui; Lian Duan; Chen Jin; Qingshan Zheng; Yuejin Yang
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

8.  Lactobacillus rhamnosus GR-1 Attenuates Induction of Hypertrophy in Cardiomyocytes but Not through Secreted Protein MSP-1 (p75).

Authors:  Grace Ettinger; Jeremy P Burton; Gregory B Gloor; Gregor Reid
Journal:  PLoS One       Date:  2017-01-13       Impact factor: 3.240

9.  Long-term administration of pyridostigmine attenuates pressure overload-induced cardiac hypertrophy by inhibiting calcineurin signalling.

Authors:  Yi Lu; Ming Zhao; Jin-Jun Liu; Xi He; Xiao-Jiang Yu; Long-Zhu Liu; Lei Sun; Li-Na Chen; Wei-Jin Zang
Journal:  J Cell Mol Med       Date:  2017-03-10       Impact factor: 5.310

10.  Radix et Rhizoma Ginseng chemoprevents both initiation and promotion of cutaneous carcinoma by enhancing cell-mediated immunity and maintaining redox homeostasis.

Authors:  Suyun Yu; Siliang Wang; Shuai Huang; Wei Wang; Zhonghong Wei; Yushi Ding; Aiyun Wang; Shile Huang; Wenxing Chen; Yin Lu
Journal:  J Ginseng Res       Date:  2019-05-21       Impact factor: 6.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.